Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px
Organisation › Details

TxCell S.A. (Euronext Paris: TXCL)

TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave®, TxCell’s lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn’s disease patients. Col-Treg, the TxCell's second drug candidate developed as a treatment for autoimmune uveitis, is expected to enter in clinical studies in the near future. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 47 employees. *

 

Period Start 2001-01-01 splitoff
  Predecessor Inserm (National Institute for Health and Medical Research, FR)
Person Person Boissel, Stéphane (TxCell 201504– CEO before Genclis + Transgene + Innate Pharma + Lazard)
     
  Street Allée de la Nertière
Les Cardoulines HT1
  City 06560 Valbonne – Sophia Antipolis
  Tel +33-4-9721-8300
    Address record changed: 2018-07-24
     
Basic data Employees B: 11 to 50 (2017-12-31)
  Currency EUR
  Annual sales 2,234,000 (revenue + other income (2017) 2017-12-31)
  Profit -10,911,000 (2016-12-31)
  Cash 4,910,000 (2017-12-31)
     
    * Document for �About Section�: TxCell S.A.. (3/10/16). "Press Release: TxCell 2015 Results and Update on Strategy and Outlook". Valbonne.
     
   
Record changed: 2018-10-30

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for TxCell S.A. (Euronext Paris: TXCL)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top